2021 – Bibliose

Prevalence and determinants of iron deficiency in cardiac amyloidosis.

5 mai 2022

admin_bibliose

Dr Benoît LEQUEUX : Cardiologue CHU de Poitiers

Prevalence and determinants of iron deficiency in cardiac amyloidosis. https://pubmed.ncbi.nlm.nih.gov/35128833/.

PMID : 35128833

2021, REPLAY

Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS).

5 mai 2022

admin_bibliose

Pr François TOURNOUX : Cardiologue - CHU de Montréal CANADA

Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS). https://pubmed.ncbi.nlm.nih.gov/35451899/

PMID : 35451899

2021, REPLAY

Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.

21 avril 2022

admin_bibliose

Dr Eve CARIOU - Cardiologue CHU de Toulouse

Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.

https://pubmed.ncbi.nlm.nih.gov/33129740/

PMID : 33129740

2021, REPLAY

Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])

21 avril 2022

admin_bibliose

Dr Zoubida TAZI MEZALEK - Cardiologue CHU de Rabat MAROC

Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]) https://pubmed.ncbi.nlm.nih.gov/33667442/

PMID : 33667442

2021, REPLAY

Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.

7 avril 2022

admin_bibliose

Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis.

Dr Martin NICOL : Cardiologue APHP Lariboisière - Paris

https://pubmed.ncbi.nlm.nih.gov/35292807/

PMID : 35292807

2021, REPLAY

Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).

7 avril 2022

admin_bibliose

Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).

Dr Clément BECLE Cardiologique - Centre Cardiologique de l'Ouest Lyonnais - Lyon

https://pubmed.ncbi.nlm.nih.gov/33220323/

PMID : 33220323

2021, REPLAY

The role of serial (99m)Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis

18 novembre 2021

admin_bibliose

Pierre TROISFONTAINES - Cardiologue CHR de la Citadelle Liège - BELGIQUE

The role of serial (99m)Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis.

https://pubmed.ncbi.nlm.nih.gov/34704883/

PMID : 34704883

2021, REPLAY

Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.

18 novembre 2021

admin_bibliose

Erwan DONAL : cardiologue CHU de Rennes

Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT. https://pubmed.ncbi.nlm.nih.gov/34509404/

PMID : 34509404

2021, REPLAY

Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation.

4 novembre 2021

admin_bibliose

Thibaut WAJCHERT - Dr Junior au CHU de Versailles

Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation.

https://pubmed.ncbi.nlm.nih.gov/32981389/

PMID : 32981389

2021, REPLAY

Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis

4 novembre 2021

admin_bibliose

Damien EYHARTS - cardiologue CHU de Toulouse

Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis

https://pubmed.ncbi.nlm.nih.gov/34643339/

PMID : 34643339

2021, REPLAY